Tenaya Therapeutics to Announce New Interim Data from MyPEAK™-1 Phase 1b/2 Trial of TN-201 for Adults with MYBPC3-Associated HCM on Wednesday, June 3, 2026
Tenaya Therapeutics will present new interim data from cohorts 1 and 2 of the Phase 1b/2 MyPEAK-1 trial evaluating TN-201, a gene therapy aimed at treating adults with MYBPC3-associated hypertrophic cardiomyopathy (HCM). The company highlights TN-201’s potential to address the genetic root cause of this severe heart condition through a single intra…